Background Glioblastoma is the most common and aggressive adult brain malignancy against which conventional surgery and chemoradiation provide limited benefit. Even when a good treatment response is obtained, recurrence inevitably occurs either locally (∼480%) or distally (∼420%), driven by cancer clones that are often genomically distinct from those in the primary tumour. Glioblastoma cells display a characteristic infiltrative phenotype, invading the surrounding tissue and often spreading across the whole brain. Cancer cells responsible for relapse can reside in two compartments of residual disease that are left behind after treatment: the infiltrated normal brain parenchyma and the sub-ventricular zone. However, these two sources of residual disease in glioblastoma are understudied because of the difficulty in sampling these regions during surgery. Patient and methods Here, we present the results of whole-exome sequencing of 69 multi-region samples collected using fluorescence-guided resection from 11 patients, including the infiltrating tumour margin and the sub-ventricular zone for each patient, as well as matched blood. We used a phylogenomic approach to dissect the spatio-temporal evolution of each tumour and unveil the relation between residual disease and the main tumour mass. We also analysed two patients with paired primary-recurrence samples with matched residual disease. Results Our results suggest that infiltrative subclones can arise early during tumour growth in a subset of patients. After treatment, the infiltrative subclones may seed the growth of a recurrent tumour, thus representing the 'missing link' between the primary tumour and recurrent disease. Conclusions These results are consistent with recognised clinical phenotypic behaviour and suggest that more specific therapeutic targeting of cells in the infiltrated brain parenchyma may improve patient's outcome.

Evolutionary dynamics of residual disease in human glioblastoma / Spiteri, I.; Caravagna, G.; Cresswell, G. D.; Vatsiou, A.; Nichol, D.; Acar, A.; Ermini, L.; Chkhaidze, K.; Werner, B.; Mair, R.; Brognaro, E.; Verhaak, R. G. W.; Sanguinetti, G.; Piccirillo, S. G. M.; Watts, C.; Sottoriva, A.. - In: ANNALS OF ONCOLOGY. - ISSN 0923-7534. - 30:3(2019), pp. 456-463. [10.1093/annonc/mdy506]

Evolutionary dynamics of residual disease in human glioblastoma

Sanguinetti G.;
2019-01-01

Abstract

Background Glioblastoma is the most common and aggressive adult brain malignancy against which conventional surgery and chemoradiation provide limited benefit. Even when a good treatment response is obtained, recurrence inevitably occurs either locally (∼480%) or distally (∼420%), driven by cancer clones that are often genomically distinct from those in the primary tumour. Glioblastoma cells display a characteristic infiltrative phenotype, invading the surrounding tissue and often spreading across the whole brain. Cancer cells responsible for relapse can reside in two compartments of residual disease that are left behind after treatment: the infiltrated normal brain parenchyma and the sub-ventricular zone. However, these two sources of residual disease in glioblastoma are understudied because of the difficulty in sampling these regions during surgery. Patient and methods Here, we present the results of whole-exome sequencing of 69 multi-region samples collected using fluorescence-guided resection from 11 patients, including the infiltrating tumour margin and the sub-ventricular zone for each patient, as well as matched blood. We used a phylogenomic approach to dissect the spatio-temporal evolution of each tumour and unveil the relation between residual disease and the main tumour mass. We also analysed two patients with paired primary-recurrence samples with matched residual disease. Results Our results suggest that infiltrative subclones can arise early during tumour growth in a subset of patients. After treatment, the infiltrative subclones may seed the growth of a recurrent tumour, thus representing the 'missing link' between the primary tumour and recurrent disease. Conclusions These results are consistent with recognised clinical phenotypic behaviour and suggest that more specific therapeutic targeting of cells in the infiltrated brain parenchyma may improve patient's outcome.
2019
30
3
456
463
Spiteri, I.; Caravagna, G.; Cresswell, G. D.; Vatsiou, A.; Nichol, D.; Acar, A.; Ermini, L.; Chkhaidze, K.; Werner, B.; Mair, R.; Brognaro, E.; Verhaak, R. G. W.; Sanguinetti, G.; Piccirillo, S. G. M.; Watts, C.; Sottoriva, A.
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0923753419310725-main.pdf

accesso aperto

Descrizione: Open Access article
Tipologia: Versione Editoriale (PDF)
Licenza: Creative commons
Dimensione 1.16 MB
Formato Adobe PDF
1.16 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/20.500.11767/117186
Citazioni
  • ???jsp.display-item.citation.pmc??? 18
  • Scopus 40
  • ???jsp.display-item.citation.isi??? 42
social impact